Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14053987 | 0.89 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502663 | 0.88 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12503029 | 0.88 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502110 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502795 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502424 | 0.83 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502715 | 0.83 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL18861053 | 0.81 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502743 | 0.81 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL14055246 | 0.81 | PDE2A (1.00) | PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670754-B1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-24 | — | — | EP | claimed |
| EP-2714661-B1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-30 | — | — | EP | claimed |
| US-8748624-B2 | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | claimed |
| WO-2012162407-A1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | claimed |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | claimed |
| EP-2670754-B1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-9540379-B2 | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2714661-B1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-8748624-B2 | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| EP-2670754-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | Boehringer Ingelheim International GmbH (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302564-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOCREA GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012162407-A1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012104293-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302564-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE3A, PDE4A, PDE2A | PDE2A 3/4885PDE10A 22/4885 |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | PDE2A 1114/4885PDE10A 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.